{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T21:21:11Z","timestamp":1782249671645,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-026-03353-2","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T15:45:31Z","timestamp":1775144731000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Albumin Nanoparticle-Based Delivery of Oxaliplatin-Oleic Acid Prodrug for Enhanced Breast Cancer Therapy"],"prefix":"10.1208","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5888-2531","authenticated-orcid":false,"given":"Oly","family":"Katari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2141-7015","authenticated-orcid":false,"given":"S.","family":"Lokesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0932-5337","authenticated-orcid":false,"given":"Brojendra Nath","family":"Saren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8957-8875","authenticated-orcid":false,"given":"Vivek","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0131-1500","authenticated-orcid":false,"given":"Kaushik","family":"Kuche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0688-9563","authenticated-orcid":false,"given":"Sanyog","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"issue":"208","key":"3353_CR1","volume":"1","author":"R Torrisi","year":"2025","unstructured":"Torrisi R, Gerosa R, Miggiano C, Saltalamacchia G, Benvenuti C, Santoro A. Beyond failure of endocrine-based therapies in HR+\/HER2 negative advanced breast cancer: what before chemotherapy? A glimpse into the future. Crit Rev Oncol Hematol. 2025;1(208):104634.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"3353_CR2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2174\/0115680096289260240311062343","volume":"25","author":"A Debnath","year":"2025","unstructured":"Debnath A, Mazumder R. Clinical progress of targeted therapy for breast cancer: a comprehensive review. Curr Cancer Drug Targets. 2025J;25(6):555\u201373.","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"3353_CR3","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/ijc.35274","volume":"156","author":"Y Chen","year":"2025","unstructured":"Chen Y, Salas LA, Marotti JD, Jenkins NP, Cheng C, Miller TW, et al. Extensive epigenomic dysregulation is a hallmark of homologous recombination deficiency in triple-negative breast cancer. Int J Cancer. 2025;156(6):1191\u2013202.","journal-title":"Int J Cancer"},{"issue":"33","key":"3353_CR4","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.23.02722","volume":"42","author":"A Takashima","year":"2024","unstructured":"Takashima A, Hamaguchi T, Mizusawa J, Nagashima F, Ando M, Ojima H, et al. Oxaliplatin Added to Fluoropyrimidine\/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018). J Clin Oncol. 2024Nov 20;42(33):3967\u201376.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3353_CR5","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1080\/1061186X.2025.2514564","volume":"33","author":"S Li","year":"2025","unstructured":"Li S, Li T, Wang X, Rahmatulla A, Zhao Y, Zhang X, et al. Research progress of treating ulcerative colitis and colon cancer by using oral colon targeted drug delivery system based on polymer micelles. J Drug Target. 2025Oct 21;33(9):1529\u201354.","journal-title":"J Drug Target"},{"issue":"1","key":"3353_CR6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1186\/s12885-018-4185-0","volume":"18","author":"EG Gebremedhn","year":"2018","unstructured":"Gebremedhn EG, Shortland PJ, Mahns DA. The incidence of acute oxaliplatin-induced neuropathy and its impact on treatment in the first cycle: a systematic review. BMC Cancer. 2018Apr 12;18(1):410.","journal-title":"BMC Cancer"},{"issue":"24","key":"3353_CR7","doi-asserted-by":"crossref","first-page":"8790","DOI":"10.1021\/ja5038269","volume":"136","author":"YR Zheng","year":"2014","unstructured":"Zheng YR, Suntharalingam K, Johnstone TC, Yoo H, Lin W, Brooks JG, et al. Pt(IV) prodrugs designed to bind non-covalently to human serum albumin for drug delivery. J Am Chem Soc. 2014Jun 18;136(24):8790\u20138.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"3353_CR8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12885-016-2182-8","volume":"16","author":"E Ratzon","year":"2016","unstructured":"Ratzon E, Najajreh Y, Salem R, Khamaisie H, Ruthardt M, Mahajna J. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study. BMC Cancer. 2016Feb 23;16(1):140.","journal-title":"BMC Cancer"},{"issue":"116","key":"3353_CR9","volume":"1","author":"JS Kim","year":"2024","unstructured":"Kim JS, Kim DK, Moon JY, Lee MY, Cho SK. Oleic acid inhibits the migration and invasion of breast cancer cells with stemness characteristics through oxidative stress-mediated attenuation of the FAK\/AKT\/NF-\u03baB pathway. J Funct Foods. 2024May;1(116):106224.","journal-title":"J Funct Foods"},{"key":"3353_CR10","doi-asserted-by":"crossref","unstructured":"Wardana TAP, Nuringtyas TR, Wijayanti N, Hidayati L. Phytochemical analysis of agarwood (Gyrinops versteegii (Gilg.) Domke) leaves extracts as anticancer using GC-MS. AIP Conf Proc. 2019 Dec 18;2194(1):020136.","DOI":"10.1063\/1.5139868"},{"issue":"7","key":"3353_CR11","volume":"25","author":"Z Guo","year":"2024","unstructured":"Guo Z, Bergeron KF, Mounier C. Oleate promotes triple-negative breast cancer cell migration by enhancing filopodia formation through a PLD\/Cdc42-dependent pathway. Int J Mol Sci. 2024;25(7):3956.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"3353_CR12","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.7150\/thno.82920","volume":"13","author":"K Yang","year":"2023","unstructured":"Yang K, Wang X, Song C, He Z, Wang R, Xu Y, et al. The role of lipid metabolic reprogramming in tumor microenvironment. Theranostics. 2023Mar 13;13(6):1774\u2013808.","journal-title":"Theranostics"},{"issue":"1","key":"3353_CR13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13048-025-01763-7","volume":"18","author":"Z Guo","year":"2025","unstructured":"Guo Z, Li Y, Guo Y, Zhang A, Huo X, Song Y, et al. Oleic acid activates TGF\u03b2-Smad3 signaling to promote ovarian cancer progression. J Ovarian Res. 2025Aug 11;18(1):180.","journal-title":"J Ovarian Res"},{"issue":"3","key":"3353_CR14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1194\/jlr.M074260","volume":"58","author":"AH Huber","year":"2017","unstructured":"Huber AH, Kleinfeld AM. Unbound free fatty acid profiles in human plasma and the unexpected absence of unbound palmitoleate. J Lipid Res. 2017;58(3):578\u201385.","journal-title":"J Lipid Res"},{"issue":"2","key":"3353_CR15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.chembiol.2023.10.012","volume":"31","author":"J Mann","year":"2024","unstructured":"Mann J, Reznik E, Santer M, Fongheiser MA, Smith N, Hirschhorn T, et al. Ferroptosis inhibition by oleic acid mitigates iron-overload-induced injury. Cell Chem Biol. 2024Feb 15;31(2):249-264.e7.","journal-title":"Cell Chem Biol"},{"issue":"16","key":"3353_CR16","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.3390\/polym15163354","volume":"15","author":"C Li","year":"2023","unstructured":"Li C, Zhang D, Pan Y, Chen B. Human serum albumin based nanodrug delivery systems: recent advances and future perspective. Polymers. 2023A;15(16):3354.","journal-title":"Polymers"},{"issue":"15","key":"3353_CR17","doi-asserted-by":"crossref","first-page":"1329636","DOI":"10.3389\/fphar.2024.1329636","volume":"23","author":"Q Ji","year":"2024","unstructured":"Ji Q, Zhu H, Qin Y, Zhang R, Wang L, Zhang E, et al. GP60 and SPARC as albumin receptors: key targeted sites for the delivery of antitumor drugs. Front Pharmacol. 2024Jan;23(15):1329636.","journal-title":"Front Pharmacol"},{"issue":"4","key":"3353_CR18","doi-asserted-by":"crossref","first-page":"728","DOI":"10.3390\/pharmaceutics14040728","volume":"14","author":"H Cho","year":"2022","unstructured":"Cho H, Jeon SI, Ahn CH, Shim MK, Kim K. Emerging albumin-binding anticancer drugs for tumor-targeted drug delivery: current understandings and clinical translation. Pharmaceutics. 2022M;14(4):728.","journal-title":"Pharmaceutics"},{"issue":"38","key":"3353_CR19","doi-asserted-by":"crossref","first-page":"12587","DOI":"10.1039\/D1SC03311E","volume":"12","author":"H Schueffl","year":"2021","unstructured":"Schueffl H, Theiner S, Hermann G, Mayr J, Fronik P, Groza D, et al. Albumin-targeting of an oxaliplatin-releasing platinum(IV) prodrug results in pronounced anticancer activity due to endocytotic drug uptake in vivo. Chem Sci. 2021Oct 6;12(38):12587\u201399.","journal-title":"Chem Sci"},{"issue":"7","key":"3353_CR20","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1021\/acs.molpharmaceut.6b00363","volume":"13","author":"H Li","year":"2016","unstructured":"Li H, Quan J, Zhang M, Yung BC, Cheng X, Liu Y, et al. Lipid-Albumin Nanoparticles (LAN) for Therapeutic Delivery of Antisense Oligonucleotide against HIF-1\u03b1. Mol Pharm. 2016Jul 5;13(7):2555\u201362.","journal-title":"Mol Pharm"},{"issue":"5\u20136","key":"3353_CR21","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1080\/1061186X.2018.1433678","volume":"26","author":"H Li","year":"2018","unstructured":"Li H, Liu Y, Chen L, Liu Q, Qi S, Cheng X, et al. Folate receptor-targeted lipid-albumin nanoparticles (F-LAN) for therapeutic delivery of an Akt1 antisense oligonucleotide. J Drug Target. 2018;26(5\u20136):466\u201373.","journal-title":"J Drug Target"},{"issue":"6","key":"3353_CR22","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1021\/acsbiomaterials.1c01582","volume":"8","author":"T Date","year":"2022","unstructured":"Date T, Kuche K, Chaudhari D, Ghadi R, Sahel DK, Chitkara D, et al. Hitting multiple cellular targets in triple-negative breast cancer using dual-action Cisplatin(IV) prodrugs for safer synergistic chemotherapy. ACS Biomater Sci Eng. 2022J;8(6):2349\u201362.","journal-title":"ACS Biomater Sci Eng"},{"key":"3353_CR23","doi-asserted-by":"crossref","unstructured":"Abhang K, Dighe S, Katari O, Yadav V, Jain S. Dual acting oxaliplatin (IV) prodrug loaded albumin nanoparticles for safer synergistic anticancer action against triple negative breast cancer. Drug Deliv Transl Res. 2025 Dec 1;15(12):4550\u201370.","DOI":"10.1007\/s13346-025-01833-9"},{"issue":"5","key":"3353_CR24","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1021\/acs.molpharmaceut.1c00844","volume":"19","author":"T Date","year":"2022","unstructured":"Date T, Kuche K, Ghadi R, Kumar P, Jain S. Understanding the Role of Axial Ligands in Modulating the Biopharmaceutical Outcomes of Cisplatin(IV) Derivatives. Mol Pharm. 2022May 2;19(5):1325\u201337.","journal-title":"Mol Pharm"},{"issue":"9","key":"3353_CR25","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1021\/mp400311j","volume":"10","author":"AK Jain","year":"2013","unstructured":"Jain AK, Thanki K, Jain S. Co-encapsulation of tamoxifen and quercetin in polymeric nanoparticles: implications on oral bioavailability, antitumor efficacy, and drug-induced toxicity. Mol Pharm. 2013Sep 3;10(9):3459\u201374.","journal-title":"Mol Pharm"},{"issue":"11","key":"3353_CR26","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1007\/s11095-017-2238-8","volume":"34","author":"V Kushwah","year":"2017","unstructured":"Kushwah V, Agrawal AK, Dora CP, Mallinson D, Lamprou DA, Gupta RC, et al. Novel gemcitabine conjugated albumin nanoparticles: a potential strategy to enhance drug efficacy in pancreatic cancer treatment. Pharm Res. 2017;34(11):2295\u2013311.","journal-title":"Pharm Res"},{"issue":"4","key":"3353_CR27","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s40139-021-00227-z","volume":"9","author":"S Sharma","year":"2021","unstructured":"Sharma S, Parveen R, Chatterji BP. Toxicology of nanoparticles in drug delivery. Curr Pathobiol Rep. 2021;9(4):133\u201344.","journal-title":"Curr Pathobiol Rep"},{"issue":"Pt 8","key":"3353_CR28","volume":"253","author":"K Kuche","year":"2023","unstructured":"Kuche K, Yadav V, Dharshini M, Ghadi R, Chaudhari D, Date T, et al. Synergistic anticancer therapy via ferroptosis using modified bovine serum albumin nanoparticles loaded with sorafenib and simvastatin. Int J Biol Macromol. 2023Dec 31;253(Pt 8):127254.","journal-title":"Int J Biol Macromol"},{"issue":"648","key":"3353_CR29","volume":"15","author":"R Ghadi","year":"2023","unstructured":"Ghadi R, Pandey PK, Gabhale A, Wadikar A, Dharshini M, Kuche K, et al. Genipin-crosslinked albumin nanoparticles containing neratinib and silibinin: A dual-death therapy for triple negative breast cancer. Int J Pharm. 2023Dec;15(648):123570.","journal-title":"Int J Pharm"},{"issue":"8","key":"3353_CR30","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1021\/acsbiomaterials.2c00594","volume":"8","author":"D Chaudhari","year":"2022","unstructured":"Chaudhari D, Katari O, Ghadi R, Kuche K, Date T, Bhargavi N, et al. Unfolding the potency of adenosine in targeting triple negative breast cancer via paclitaxel-incorporated pH-responsive stealth liposomes. ACS Biomater Sci Eng. 2022A;8(8):3473\u201384.","journal-title":"ACS Biomater Sci Eng"},{"issue":"253","key":"3353_CR31","volume":"31","author":"K Kuche","year":"2023","unstructured":"Kuche K, Yadav V, Dharshini M, Ghadi R, Chaudhari D, Date T, et al. Synergistic anticancer therapy via ferroptosis using modified bovine serum albumin nanoparticles loaded with sorafenib and simvastatin. Int J Biol Macromol. 2023Dec;31(253):127254.","journal-title":"Int J Biol Macromol"},{"issue":"149","key":"3353_CR32","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.enconman.2017.07.053","volume":"1","author":"S Niu","year":"2017","unstructured":"Niu S, Zhou Y, Yu H, Lu C, Han K. Investigation on thermal degradation properties of oleic acid and its methyl and ethyl esters through TG-FTIR. Energy Convers Manag. 2017Oct;1(149):495\u2013504.","journal-title":"Energy Convers Manag"},{"issue":"3","key":"3353_CR33","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s10973-017-6413-2","volume":"130","author":"TA Reis","year":"2017","unstructured":"Reis TA, Matos BN, Lima EM, Chaker JA, Gratieri T, Cunha-Filho MSS, et al. Oxaliplatin preformulation studies for the development of innovative topical drug delivery systems. J Therm Anal Calorim. 2017;130(3):1671\u201381.","journal-title":"J Therm Anal Calorim"},{"issue":"11","key":"3353_CR34","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1039\/D4QI00459K","volume":"11","author":"S Chen","year":"2024","unstructured":"Chen S, Zhou Q, Ng KY, Xu Z, Xu W, Zhu G. Advances in technical strategies for monitoring the reduction of platinum( iv ) complexes. Inorg Chem Front. 2024;11(11):3085\u2013118.","journal-title":"Inorg Chem Front"},{"key":"3353_CR35","doi-asserted-by":"crossref","unstructured":"Andr\u00e9s CMC, P\u00e9rez de la Lastra JM, Bustamante Munguira E, Andr\u00e9s Juan C, P\u00e9rez-Lebe\u00f1a E. Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides\u2014Current Developments in Structure-Activity Relationship. Int J Mol Sci. 2024 Jul 3;25(13):7314.","DOI":"10.3390\/ijms25137314"},{"issue":"14","key":"3353_CR36","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1039\/D3QI00968H","volume":"10","author":"A Kastner","year":"2023","unstructured":"Kastner A, Mendrina T, Bachmann F, Berger W, Keppler BK, Heffeter P, et al. Tumor-targeted dual-action NSAID-platinum(iv) anticancer prodrugs. Inorg Chem Front. 2023;10(14):4126\u201338.","journal-title":"Inorg Chem Front"},{"key":"3353_CR37","doi-asserted-by":"crossref","unstructured":"P.\u00a0Varbanov H, Ortiz D, H\u00f6fer D, Menin L, S.\u00a0Galanski M, K.\u00a0Keppler B, et al. Oxaliplatin reacts with DMSO only in the presence of water. Dalton Trans. 2017;46(28):8929\u201332.","DOI":"10.1039\/C7DT01628J"},{"issue":"1","key":"3353_CR38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42004-022-00661-z","volume":"5","author":"P Fronik","year":"2022","unstructured":"Fronik P, Gutmann M, Vician P, Stojanovic M, Kastner A, Heffeter P, et al. A platinum(IV) prodrug strategy to overcome glutathione-based oxaliplatin resistance. Commun Chem. 2022Apr 6;5(1):1\u201313.","journal-title":"Commun Chem"},{"key":"3353_CR39","doi-asserted-by":"crossref","unstructured":"B.\u00a0Mobley E, Byrd N, G.\u00a0Yim M, Gariepy R, Rieder M, Ward S. Glutathione sensitive vesicles prepared from supramolecular amphiphiles. Soft Matter. 2021;17(42):9664\u20139.","DOI":"10.1039\/D1SM01238J"},{"issue":"12","key":"3353_CR40","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41419-022-05477-2","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Yue P, Dickinson CF, Yang JK, Datanagan K, Zhai N, et al. Natural product preferentially targets redox and metabolic adaptations and aberrantly active STAT3 to inhibit breast tumor growth in vivo. Cell Death Dis. 2022Dec 6;13(12):1022.","journal-title":"Cell Death Dis"},{"issue":"113","key":"3353_CR41","volume":"1","author":"P\u00d3 Conghaile","year":"2020","unstructured":"Conghaile P\u00d3, Kumar R, Ferrer ML, Leech D. Glucose oxidation by enzyme electrodes using genipin to crosslink chitosan, glucose oxidase and amine-containing osmium redox complexes. Electrochem Commun. 2020;1(113):106703.","journal-title":"Electrochem Commun"},{"key":"3353_CR42","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.2147\/IJN.S318124","volume":"16","author":"H Huang","year":"2021","unstructured":"Huang H, Liu Q, Zhang T, Zhang J, Zhou J, Jing X, et al. Farnesylthiosalicylic Acid-Loaded Albumin Nanoparticle Alleviates Renal Fibrosis by Inhibiting Ras\/Raf1\/p38 Signaling Pathway. Int J Nanomedicine. 2021;16:6441\u201353.","journal-title":"Int J Nanomedicine"},{"issue":"50","key":"3353_CR43","volume":"1","author":"K Skoll","year":"2023","unstructured":"Skoll K, Palmetzhofer J, Lummerstorfer M, Anzengruber M, Gabor F, Wirth M. Human serum albumin nanoparticles as a versatile vehicle for targeted delivery of antibiotics to combat bacterial infections. Nanomedicine Nanotechnol Biol Med. 2023;1(50):102685.","journal-title":"Nanomedicine Nanotechnol Biol Med"},{"issue":"3","key":"3353_CR44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057681","volume":"8","author":"A Mathur","year":"2013","unstructured":"Mathur A, Blais S, Goparaju CMV, Neubert T, Pass H, Levon K. Development of a biosensor for detection of pleural mesothelioma cancer biomarker using surface imprinting. PLoS One. 2013M;8(3):e57681.","journal-title":"PLoS One"},{"issue":"2","key":"3353_CR45","doi-asserted-by":"crossref","first-page":"613","DOI":"10.17798\/bitlisfen.1068508","volume":"11","author":"ED Kurtul","year":"2022","unstructured":"Kurtul ED, Yurtsever M\u00c7. Genipin Crosslinked Human Serum Albumin Nanoparticles. Bitlis Eren \u00dcniversitesi Fen Bilim Derg. 2022Jun 30;11(2):613\u20139.","journal-title":"Bitlis Eren \u00dcniversitesi Fen Bilim Derg"},{"issue":"330","key":"3353_CR46","volume":"15","author":"R Luo","year":"2020","unstructured":"Luo R, Lin M, Zhang C, Shi J, Zhang S, Chen Q, et al. Genipin-crosslinked human serum albumin coating using a tannic acid layer for enhanced oral administration of curcumin in the treatment of ulcerative colitis. Food Chem. 2020Nov;15(330):127241.","journal-title":"Food Chem"},{"key":"3353_CR47","first-page":"41","volume":"3","author":"S Paul","year":"2017","unstructured":"Paul S, Sepay N, Sarkar S, Roy P, Dasgupta S, Sardar P, et al. Interaction of Serum Albumins with Fluorescent Ligand 4-Azido Coumarin: Spectroscopic Analysis and Molecular Docking Studies. New J Chem. 2017Nov;3:41.","journal-title":"New J Chem"},{"issue":"648","key":"3353_CR48","volume":"15","author":"R Ghadi","year":"2023","unstructured":"Ghadi R, Pandey PK, Gabhale A, Wadikar A, Dharshini M, Kuche K, et al. Genipin-crosslinked albumin nanoparticles containing neratinib and silibinin: A dual-death therapy for triple negative breast cancer. Int J Pharm. 2023Dec;15(648):123570.","journal-title":"Int J Pharm"},{"issue":"1\u20132","key":"3353_CR49","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijpharm.2011.12.045","volume":"424","author":"Y Wang","year":"2012","unstructured":"Wang Y, Kho K, Cheow WS, Hadinoto K. A comparison between spray drying and spray freeze drying for dry powder inhaler formulation of drug-loaded lipid-polymer hybrid nanoparticles. Int J Pharm. 2012Mar 15;424(1\u20132):98\u2013106.","journal-title":"Int J Pharm"},{"issue":"29","key":"3353_CR50","doi-asserted-by":"crossref","first-page":"0245","DOI":"10.34133\/bmr.0245","volume":"3","author":"H Iqbal","year":"2025","unstructured":"Iqbal H, Razzaq A, Yuan Z, Zhai L, Wang Y, Ur-Rehman U, et al. Albumin Nanocages with Methotrexate and Chondroitin Sulfate as a Dual pH\/GSH-Responsive Tumor Targeting Nanomedicine for Synergistic Cancer Therapy. Biomater Res. 2025Sep;3(29):0245.","journal-title":"Biomater Res"},{"issue":"15","key":"3353_CR51","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1021\/acs.jcim.3c00625","volume":"63","author":"C Wennberg","year":"2023","unstructured":"Wennberg C, Lundborg M, Lindahl E, Norl\u00e9n L. Understanding Drug Skin Permeation Enhancers Using Molecular Dynamics Simulations. J Chem Inf Model. 2023Jul 18;63(15):4900\u201311.","journal-title":"J Chem Inf Model"},{"issue":"37","key":"3353_CR52","doi-asserted-by":"crossref","first-page":"17184","DOI":"10.1039\/D5SC04365D","volume":"16","author":"R Yadav","year":"2025","unstructured":"Yadav R, Adikessavane N, Ram\u00a0Mahato R, Maiti S. Decoding information entropy of fatty acid and phospholipid vesicles via ordering combinatorial output of hydrazones. Chem Sci. 2025;16(37):17184\u201392.","journal-title":"Chem Sci"},{"issue":"2","key":"3353_CR53","volume":"14","author":"J Wang","year":"2021","unstructured":"Wang J, Tao J, Jia S, Wang M, Jiang H, Du Z. The protein-binding behavior of platinum anticancer drugs in blood revealed by mass spectrometry. Pharmaceuticals. 2021;14(2):104.","journal-title":"Pharmaceuticals"},{"issue":"2","key":"3353_CR54","doi-asserted-by":"crossref","first-page":"64","DOI":"10.4236\/jbnb.2016.72008","volume":"7","author":"MA Elblbesy","year":"2016","unstructured":"Elblbesy MA. Hemocompatibility of Albumin Nanoparticles as a Drug Delivery System\u2014An in Vitro Study. J Biomater Nanobiotechnology. 2016Mar 31;7(2):64\u201371.","journal-title":"J Biomater Nanobiotechnology"},{"issue":"1","key":"3353_CR55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12645-023-00239-x","volume":"15","author":"Q Jiang","year":"2024","unstructured":"Jiang Q, Yao F, An Y, Lai X, Li X, Yu Z, et al. Novel nanotherapeutics for cancer immunotherapy by albumin nanoparticles functionalized with PD-1 and PD-L1 aptamers. Cancer Nanotechnol. 2024Jan 6;15(1):3.","journal-title":"Cancer Nanotechnol"},{"issue":"213","key":"3353_CR56","volume":"1","author":"SS Kunde","year":"2022","unstructured":"Kunde SS, Wairkar S. Targeted delivery of albumin nanoparticles for breast cancer: a review. Colloids Surf B Biointerfaces. 2022;1(213):112422.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"7","key":"3353_CR57","first-page":"5205","volume":"2","author":"CM Kummitha","year":"2012","unstructured":"Kummitha CM, Malamas AS, Lu ZR. Albumin pre-coating enhances intracellular siRNA delivery of multifunctional amphiphile\/siRNA nanoparticles. Int J Nanomedicine. 2012;2(7):5205\u201314.","journal-title":"Int J Nanomedicine"},{"issue":"4","key":"3353_CR58","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/15548627.2025.2452149","volume":"21","author":"G Xu","year":"2025","unstructured":"Xu G, Zhang Q, Cheng R, Qu J, Li W. Survival strategies of cancer cells: the role of macropinocytosis in nutrient acquisition, metabolic reprogramming, and therapeutic targeting. Autophagy. 2025;21(4):693\u2013718.","journal-title":"Autophagy"},{"issue":"20","key":"3353_CR59","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.2147\/IJN.S500997","volume":"19","author":"I Stukan","year":"2025","unstructured":"Stukan I, \u017buk A, Pukacka K, Mierzejewska J, Paw\u0142owski J, Kowalski B, et al. Wolf in Sheep’s Clothing: Taming Cancer’s Resistance with Human Serum Albumin? Int J Nanomedicine. 2025Mar;19(20):3493\u2013525.","journal-title":"Int J Nanomedicine"},{"issue":"2","key":"3353_CR60","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0169-409X(02)00180-1","volume":"55","author":"RB Greenwald","year":"2003","unstructured":"Greenwald RB, Choe YH, McGuire J, Conover CD. Effective drug delivery by PEGylated drug conjugates. Adv Drug Deliv Rev. 2003Feb 10;55(2):217\u201350.","journal-title":"Adv Drug Deliv Rev"},{"issue":"3","key":"3353_CR61","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/1061186X.2015.1051049","volume":"24","author":"P Kumari","year":"2016","unstructured":"Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target. 2016Mar 15;24(3):179\u201391.","journal-title":"J Drug Target"},{"issue":"8","key":"3353_CR62","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1021\/acs.jmedchem.3c02393","volume":"67","author":"F Navas","year":"2024","unstructured":"Navas F, Chocarro-Calvo A, Iglesias-Hern\u00e1ndez P, Fern\u00e1ndez-Garc\u00eda P, Morales V, Garc\u00eda-Mart\u00ednez JM, et al. Promising Anticancer Prodrugs Based on Pt(IV) Complexes with Bis-organosilane Ligands in Axial Positions. J Med Chem. 2024Apr 9;67(8):6410\u201324.","journal-title":"J Med Chem"},{"issue":"6","key":"3353_CR63","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1002\/med.21360","volume":"35","author":"X Han","year":"2015","unstructured":"Han X, Sun J, Wang Y, He Z. Recent advances in platinum (IV) complex\u2010based delivery systems to improve platinum (II) anticancer therapy. Med Res Rev. 2015;35(6):1268\u201399.","journal-title":"Med Res Rev"},{"issue":"3","key":"3353_CR64","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09192","volume":"8","author":"HA Hussein","year":"2022","unstructured":"Hussein HA, Kassim MNI, Maulidiani M, Abas F, Abdullah MA. Cytotoxicity and 1H NMR metabolomics analyses of microalgal extracts for synergistic application with Tamoxifen on breast cancer cells with reduced toxicity against Vero cells. Heliyon. 2022Mar 1;8(3):e09192.","journal-title":"Heliyon"},{"issue":"1","key":"3353_CR65","doi-asserted-by":"crossref","first-page":"15129","DOI":"10.1038\/s41598-017-15003-6","volume":"7","author":"HS Frislev","year":"2017","unstructured":"Frislev HS, Boye TL, Nylandsted J, Otzen D. Liprotides kill cancer cells by disrupting the plasma membrane. Sci Rep. 2017Nov 9;7(1):15129.","journal-title":"Sci Rep"},{"issue":"4","key":"3353_CR66","first-page":"930","volume":"3","author":"I Hassanin","year":"2020","unstructured":"Hassanin I, Elzoghby A. Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance. Cancer Drug Resist. 2020;3(4):930.","journal-title":"Cancer Drug Resist"},{"issue":"4","key":"3353_CR67","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/14786419.2014.945172","volume":"29","author":"S K\u0131z\u0131l\u015fahin","year":"2015","unstructured":"K\u0131z\u0131l\u015fahin S, Nalbantsoy A, Karabay Yava\u015fo\u011flu N\u00dc. In vitro synergistic efficacy of conjugated linoleic acid, oleic acid, safflower oil and taxol cytotoxicity on PC3 cells. Nat Prod Res. 2015Feb 16;29(4):378\u201382.","journal-title":"Nat Prod Res"},{"issue":"10","key":"3353_CR68","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.devcel.2021.04.013","volume":"56","author":"LA Broadfield","year":"2021","unstructured":"Broadfield LA, Pane AA, Talebi A, Swinnen JV, Fendt SM. Lipid metabolism in cancer: New perspectives and emerging mechanisms. Dev Cell. 2021May 17;56(10):1363\u201393.","journal-title":"Dev Cell"},{"issue":"Pt 8","key":"3353_CR69","volume":"253","author":"K Kuche","year":"2023","unstructured":"Kuche K, Yadav V, Dharshini M, Ghadi R, Chaudhari D, Date T, et al. Synergistic anticancer therapy via ferroptosis using modified bovine serum albumin nanoparticles loaded with sorafenib and simvastatin. Int J Biol Macromol. 2023Dec 31;253(Pt 8):127254.","journal-title":"Int J Biol Macromol"},{"issue":"3","key":"3353_CR70","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jphs.2022.01.006","volume":"148","author":"T Miyamoto","year":"2022","unstructured":"Miyamoto T, Domoto R, Sekiguchi F, Kamaguchi R, Nishimura R, Matsuno M, et al. Development of hepatic impairment aggravates chemotherapy-induced peripheral neuropathy following oxaliplatin treatment: Evidence from clinical and preclinical studies. J Pharmacol Sci. 2022Mar 1;148(3):315\u201325.","journal-title":"J Pharmacol Sci"}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03353-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-026-03353-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-026-03353-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:49:16Z","timestamp":1780390156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-026-03353-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":70,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["3353"],"URL":"https:\/\/doi.org\/10.1208\/s12249-026-03353-2","relation":{},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing financial or personal relationships that could have influenced the work reported in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"167"}}